AKTX

Akari Therapeutics, Plc

Price Chart

Latest Quote

$15.07

-0.77 (-4.86%)

Current Price

Previous Close	$15.84
Open	$15.88
Day High	$15.92
Day Low	$14.01
Volume	59,961

Fetched: 2026-06-06T11:44:50

Stock Information

Shares Outstanding	1.14M
Total Debt	$732K
Cash Equivalents	$2.77M
Net Income	$-28.05M
Sector	Healthcare
Industry	Biotechnology
Market Cap	$17.25M
Exchange	NCM

🌐 Visit Website

📊 Comprehensive Analysis

Company Data

Enterprise Value	$1.38T
Income	$-28.05M
Book/sh	$12.56
Cash/sh	$2.42
Employees	5

Financial Ratios

Quick Ratio	0.21
Current Ratio	0.27
Debt/Eq	5.09

Returns & Margins

ROA	-17.97%
ROE	-155.28%

Ownership

Insider Ownership	34.94%
Institutional Ownership	8.42%
Insider & Institutional transactions data not available

Valuation Ratios

Forward P/E	-1.08
P/B	1.20

Analyst Data

Recommendation	none
Target Price	$26.78

Technical Indicators

SMA20	$10.25
SMA50	$7.18
SMA200	$16.91
RSI	66.23
ATR	4.6351

Shares Float	41.33B
Short Float	20.60%
Short Ratio	1.13
Volatility	1.33
Rel Volume	0.03

Performance History

Week	-8.28%
Month	+158.93%
Quarter	+50.10%
6 Months	+10.81%
YTD	+29.91%
Year	-72.09%
3 Years	-89.36%
5 Years	-98.95%
10 Years	-99.87%

Stock Score: ⭐ Premium

Based on debt, profitability, growth, and cash flow metrics

⭐ Premium Feature

Recent Price History

Date	Close	Volume
2026-06-05	$15.07	60,100
2026-06-04	$15.84	69,100
2026-06-03	$14.98	59,600
2026-06-02	$14.63	265,400
2026-06-01	$13.43	195,800
2026-05-29	$16.43	542,500
2026-05-28	$22.05	1,653,200
2026-05-27	$15.93	486,900
2026-05-26	$17.81	2,536,600
2026-05-22	$18.27	34,043,100
2026-05-21	$5.14	6,266,300
2026-05-20	$3.43	17,000
2026-05-19	$3.74	26,300
2026-05-18	$3.50	9,800
2026-05-15	$3.49	13,200
2026-05-14	$3.70	40,300
2026-05-13	$3.15	72,100
2026-05-12	$3.06	109,200
2026-05-11	$5.15	17,200
2026-05-08	$6.25	4,300
2026-05-07	$6.58	12,000
2026-05-06	$5.82	12,300

About Akari Therapeutics, Plc

Akari Therapeutics, Plc, an oncology company, develops antibody-drug conjugates (ADC) for cancer-killing toxins. Its lead payload is PH1 to disrupt the function of spliceosomes and to trigger an immune response that leads to additional cancer cell killing. The company's lead product candidate is AKTX-101, a preclinical stage trop2-targeting ADC that combines PH1 with the trop2 antibody to treat solid tumor cancer types, including lung, breast, bladder, head and neck, gastric, pancreatic, colon, prostate, and others. Its payloads include PH1 is a novel payload that is a spliceosome modulator designed to disrupt RNA splicing within cancer cells. The company also develops AKTX-102, a novel bispecific ADC that utilizes PH1 as its payload to treat various solid tumor cancers. Akari Therapeutics, Plc is headquartered in Tampa, Florida.

📰 Latest News

European Equities Traded in the US as American Depositary Receipts Decline in Friday Trading; Rise for Week

MT Newswires • 2026-06-05T15:06:40Z

European Equities Traded in the US as American Depositary Receipts Rise in Thursday Trading

MT Newswires • 2026-06-04T15:08:32Z

European Equities Traded in the US as American Depositary Receipts Rise in Tuesday Trading

MT Newswires • 2026-06-02T15:08:08Z

European Equities Traded in the US as American Depositary Receipts Decline in Monday Trading

MT Newswires • 2026-06-01T15:11:54Z

Akari Therapeutics Highlights 1st ASCO Abstract Acceptance

IPO-Edge.com • 2026-05-28T22:33:46Z

European Equities Traded in the US as American Depositary Receipts Edge Lower Thursday

MT Newswires • 2026-05-28T15:14:11Z

European Equities Traded in the US as American Depositary Receipts Decline in Wednesday Trading

MT Newswires • 2026-05-27T15:08:11Z

European Equities Traded in the US as American Depositary Receipts Edge Higher in Friday Trading

MT Newswires • 2026-05-22T15:06:28Z

European Equities Traded in the US as American Depositary Receipts Little Changed in Thursday Trading

MT Newswires • 2026-05-21T15:05:36Z

European Equities Traded in the US as American Depositary Receipts Trend Lower in Tuesday Trading

MT Newswires • 2026-05-19T15:27:05Z

Period:

Income Statement (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Revenue
Total Revenue	$0	$0	$0	$0
Operating Revenue	$0	$0	$0	$0
Expenses
Interest Expense	$949,000	$244,000	$0	-
Total Expenses	$12,095,000	$16,647,000	$16,806,000	$23,088,000
Other Income Expense	$-5,258,000	$-2,908,000	$6,716,000	$5,294,000
Other Non Operating Income Expenses	$2,984,000	$-3,000	$-19,000	$-142,000
Net Non Operating Interest Income Expense	$-948,000	$-236,000	$82,000	$46,000
Interest Expense Non Operating	$949,000	$244,000	$0	-
Operating Expense	$12,095,000	$16,647,000	$16,806,000	$23,088,000
General And Administrative Expense	$9,280,000	$9,664,000	$11,356,000	$13,527,000
Income & Earnings
Net Income From Continuing Operation Net Minority Interest	$-17,298,000	$-19,791,000	$-10,008,000	$-17,748,000
Net Interest Income	$-948,000	$-236,000	$82,000	$46,000
Interest Income	$1,000	$8,000	$82,000	$46,000
Normalized Income	$-9,509,310	$-16,886,000	$-16,743,000	$-23,184,000
Net Income From Continuing And Discontinued Operation	$-17,298,000	$-19,791,000	$-10,008,000	$-17,748,000
Total Operating Income As Reported	$-17,275,000	$-21,643,000	$-16,806,000	$-23,088,000
Net Income Common Stockholders	$-17,298,000	$-19,791,000	$-10,008,000	$-17,748,000
Net Income	$-17,298,000	$-19,791,000	$-10,008,000	$-17,748,000
Net Income Including Noncontrolling Interests	$-17,298,000	$-19,791,000	$-10,008,000	$-17,748,000
Net Income Continuous Operations	$-17,298,000	$-19,791,000	$-10,008,000	$-17,748,000
Pretax Income	$-18,301,000	$-19,791,000	$-10,008,000	$-17,748,000
Special Income Charges	$-8,344,000	$-4,996,000	$0	-
Interest Income Non Operating	$1,000	$8,000	$82,000	$46,000
Operating Income	$-12,095,000	$-16,647,000	$-16,806,000	$-23,088,000
Per Share
Diluted EPS	$0.00	$0.00	$0.00	$-216.00
Basic EPS	$0.00	$0.00	$0.00	$-216.00
Other
Tax Effect Of Unusual Items	$-453,310	$0	$0	$0
Tax Rate For Calcs	$0	$0	$0	$0
Normalized EBITDA (Bullshit earnings)	$-9,110,000	$-16,628,000	$-16,739,000	$-28,520,000
Total Unusual Items	$-8,242,000	$-2,905,000	$6,735,000	$5,436,000
Total Unusual Items Excluding Goodwill	$-8,242,000	$-2,905,000	$6,735,000	$5,436,000
Reconciled Depreciation	$0	$14,000	$4,000	$4,000
EBITDA (Bullshit earnings)	$-17,352,000	$-19,533,000	$-10,004,000	$-23,084,000
EBIT	$-17,352,000	$-19,547,000	$-10,008,000	$-23,088,000
Diluted Average Shares	$841,602	$298,600	$122,362	$78,043
Basic Average Shares	$841,602	$298,600	$122,362	$78,043
Diluted NI Availto Com Stockholders	$-17,298,000	$-19,791,000	$-10,008,000	$-17,748,000
Tax Provision	$-1,003,000	$0	-	-
Other Special Charges	$3,164,000	-	-	-
Impairment Of Capital Assets	$5,180,000	$0	-	-
Restructuring And Mergern Acquisition	$0	$4,996,000	$0	-
Gain On Sale Of Security	$102,000	$2,091,000	$6,735,000	$5,436,000
Research And Development	$2,815,000	$6,983,000	$5,450,000	$9,561,000
Selling General And Administration	$9,280,000	$9,664,000	$11,356,000	$13,527,000
Other Gand A	$9,280,000	$9,664,000	$11,356,000	$13,527,000

Fetched: 2026-06-01

Balance Sheet (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Assets
Net Tangible Assets	$-14,102,000	$-25,381,000	$-243,000	$1,774,000
Total Assets	$47,892,000	$50,562,000	$4,355,000	$13,832,000
Total Non Current Assets	$42,430,000	$47,610,000	$14,000	$17,000
Goodwill And Other Intangible Assets	$42,430,000	$47,610,000	$14,000	$17,000
Other Intangible Assets	$34,000,000	$39,180,000	$14,000	$17,000
Current Assets	$5,462,000	$2,952,000	$4,341,000	$13,815,000
Other Current Assets	$14,000	$201,000	$197,000	$100,000
Restricted Cash	$60,000	$60,000	$0	-
Prepaid Assets	$185,000	$92,000	$299,000	$465,000
Cash Cash Equivalents And Short Term Investments	$5,203,000	$2,599,000	$3,845,000	$13,250,000
Cash And Cash Equivalents	$5,203,000	$2,599,000	$3,845,000	$13,250,000
Cash Financial	$5,203,000	$2,599,000	$3,845,000	$13,250,000
Debt
Total Debt	$754,000	$3,260,000	-	-
Current Debt And Capital Lease Obligation	$754,000	$3,260,000	-	-
Current Debt	$754,000	$3,260,000	-	-
Other Current Borrowings	$673,000	$950,000	-	-
Net Debt	-	$661,000	-	-
Liabilities
Total Liabilities Net Minority Interest	$19,564,000	$28,333,000	$4,584,000	$12,041,000
Total Non Current Liabilities Net Minority Interest	$7,213,000	$8,423,000	$0	$0
Other Non Current Liabilities	$31,000	$383,000	-	-
Derivative Product Liabilities	$230,000	$0	-	-
Non Current Deferred Liabilities	$6,952,000	$8,040,000	$0	-
Non Current Deferred Taxes Liabilities	$6,952,000	$8,040,000	$0	-
Current Liabilities	$12,351,000	$19,910,000	$4,584,000	$12,041,000
Other Current Liabilities	$485,000	$1,106,000	$1,347,000	$7,946,000
Current Notes Payable	$81,000	$2,310,000	$0	-
Payables And Accrued Expenses	$10,332,000	$15,071,000	$3,050,000	$2,669,000
Payables	$8,770,000	$12,407,000	$1,671,000	$947,000
Accounts Payable	$8,770,000	$12,407,000	$1,671,000	$947,000
Equity
Common Stock Equity	$28,328,000	$22,229,000	$-229,000	$1,791,000
Total Equity Gross Minority Interest	$28,328,000	$22,229,000	$-229,000	$1,791,000
Stockholders Equity	$28,328,000	$22,229,000	$-229,000	$1,791,000
Gains Losses Not Affecting Retained Earnings	$-782,000	$-738,000	$-1,040,000	$-771,000
Other Equity Adjustments	$-782,000	$-738,000	$-1,040,000	$-771,000
Retained Earnings	$-264,550,000	$-247,252,000	$-227,461,000	$-217,453,000
Other
Ordinary Shares Number	$90,536,879,533	$53,186,919,523	$13,234,315,298	$7,444,917,123
Share Issued	$90,536,879,533	$53,186,919,523	$13,234,315,298	$7,444,917,123
Tangible Book Value	$-14,102,000	$-25,381,000	$-243,000	$1,774,000
Invested Capital	$29,082,000	$25,489,000	$-229,000	$1,791,000
Working Capital	$-6,889,000	$-16,958,000	$-243,000	$1,774,000
Total Capitalization	$28,328,000	$22,229,000	$-229,000	$1,791,000
Additional Paid In Capital	$293,660,000	$264,900,000	$226,948,000	$219,270,000
Capital Stock	$0	$5,319,000	$1,324,000	$745,000
Common Stock	$0	$5,319,000	$1,324,000	$745,000
Pensionand Other Post Retirement Benefit Plans Current	$780,000	$473,000	$187,000	$1,426,000
Current Accrued Expenses	$1,562,000	$2,664,000	$1,379,000	$1,722,000
Goodwill	$8,430,000	$8,430,000	-	-
Net PPE	-	-	-	-
Accumulated Depreciation	-	-	-	-
Gross PPE	-	-	-	-
Machinery Furniture Equipment	-	-	-	-

Fetched: 2026-06-01

Cash Flow Statement (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Free Cash Flow
Free Cash Flow	$-10,568,000	$-12,552,000	$-16,432,000	$-21,504,000
Operating Activities
Operating Cash Flow	$-10,568,000	$-12,552,000	$-16,432,000	$-21,504,000
Cash Flow From Continuing Operating Activities	$-10,568,000	$-12,552,000	$-16,432,000	$-21,504,000
Operating Gains Losses	$2,520,000	$-1,830,000	$-6,854,000	$-5,317,000
Investing Activities
Investing Cash Flow	$0	$382,000	$0	-
Cash Flow From Continuing Investing Activities	$0	$382,000	$0	-
Financing Activities
Issuance Of Capital Stock	$10,725,000	$11,815,000	$7,016,000	$25,194,000
Financing Cash Flow	$13,171,000	$10,988,000	$7,020,000	$25,288,000
Cash Flow From Continuing Financing Activities	$13,171,000	$10,988,000	$7,020,000	$25,288,000
Net Common Stock Issuance	$10,725,000	$11,815,000	$7,016,000	$25,194,000
Common Stock Issuance	$10,725,000	$11,815,000	$7,016,000	$25,194,000
Net Other Financing Charges	-	$26,000	-	-
Other
Repayment Of Debt	$-1,052,000	$-1,855,000	$0	-
Issuance Of Debt	$2,099,000	$1,000,000	$0	-
Interest Paid Supplemental Data	$101,000	$143,000	$0	-
Income Tax Paid Supplemental Data	$0	$0	-	-
End Cash Position	$5,263,000	$2,659,000	$3,845,000	$13,250,000
Beginning Cash Position	$2,659,000	$3,845,000	$13,250,000	$9,361,000
Effect Of Exchange Rate Changes	$1,000	$-4,000	$7,000	$105,000
Changes In Cash	$2,603,000	$-1,182,000	$-9,412,000	$3,784,000
Proceeds From Stock Option Exercised	$1,399,000	$2,000	$4,000	$94,000
Net Issuance Payments Of Debt	$1,047,000	$-855,000	$0	-
Net Short Term Debt Issuance	$1,047,000	$-855,000	$0	-
Short Term Debt Payments	$-1,052,000	$-1,855,000	$0	-
Short Term Debt Issuance	$2,099,000	$1,000,000	$0	-
Net Business Purchase And Sale	$0	$382,000	$0	-
Sale Of Business	$0	$382,000	$0	-
Change In Working Capital	$-404,000	$6,539,000	$-866,000	$822,000
Change In Payables And Accrued Expense	$-998,000	$5,223,000	$-936,000	$-877,000
Change In Prepaid Assets	$594,000	$1,316,000	$70,000	$1,699,000
Other Non Cash Items	$-2,368,000	$271,000	$142,000	-
Stock Based Compensation	$2,890,000	$2,245,000	$1,150,000	$735,000
Asset Impairment Charge	$5,180,000	$0	-	-
Deferred Tax	$-1,088,000	$0	-	-
Deferred Income Tax	$-1,088,000	$0	-	-
Depreciation Amortization Depletion	$0	$14,000	$4,000	$4,000
Depreciation And Amortization	$0	$14,000	$4,000	$4,000
Gain Loss On Investment Securities	$-545,000	$-2,085,000	$-6,599,000	$-4,983,000
Net Foreign Currency Exchange Gain Loss	$-99,000	$255,000	$-255,000	$-334,000
Net Income From Continuing Operations	$-17,298,000	$-19,791,000	$-10,008,000	$-17,748,000

Fetched: 2026-06-01